Sensation synthesis: Researchers overcome decades-old shortage of chemotherapy drug doxorubicin

by | Mar 16, 2026 | Health, Research

An international research team has achieved a breakthrough in the biotechnological production of doxorubicin, a key chemotherapeutic agent. The scientists identified and eliminated molecular bottlenecks that had severely limited the natural production of the active ingredient for over 50 years.

Doxorubicin has been used to treat various cancers since the 1970s, including breast cancer, bladder cancer, lymphoma, and carcinoma. More than one million patients receive the drug every year. However, bacteria naturally produce the active ingredient very inefficiently, which is why the pharmaceutical industry is dependent on expensive, multi-stage semi-synthetic processes.

The image shows how the new, optimized bacterial strain produces an increased amount of doxorubicin. At the center, the primary production mechanism (DoxA) is enhanced by a biological "power supply" (FDX and FDR) and a "molecular sponge" (DnrV). While the power supply keeps the process running at full speed, the sponge prevents the drug from clogging the system, allowing the genetically engineered cells to produce the drug with unprecedented purity and a 180% higher yield than traditional industrial processes. Photo credit: Keith Yamada
The image shows how the new, optimized bacterial strain produces an increased amount of doxorubicin. At the center, the primary production mechanism (DoxA) is enhanced by a biological “power supply” (FDX and FDR) and a “molecular sponge” (DnrV). While the power supply keeps the process running at full speed, the sponge prevents the drug from clogging the system, allowing the genetically engineered cells to produce the drug with unprecedented purity and a 180% higher yield than traditional industrial processes. Photo credit: Keith Yamada

The team of six laboratories – the University of Turku (Finland), three US and two Dutch institutions in Leiden – identified three key limitations. First, there was a lack of suitable redox partners (Fdx4 and FdR3) that provide the necessary electron flow for the key-forming enzyme. Secondly, the protein DnrV binds doxorubicin like a sponge and thus prevents feedback inhibition of production. Third, X-ray crystal structure analysis showed that the molecule is unfavorably positioned in the enzyme, which slows down the reaction rate.

Through targeted engineering of a new bacterial strain, the researchers were able to increase the doxorubicin yield by 180 percent compared to current industrial standards.

To put it into practice, the spin-off company Meta-Cells Oy was founded at the University of Turku. It is intended to commercialize the technologies and enable sustainable, fully biosynthetic production of essential antibiotics and cytostatics. This promises a more environmentally friendly and reliable supply of vital medicines.

The study was published in “Nature Communications” (DOI: 10.1038/s41467-026-69194-6).

Original Paper:

Metabolic engineering of doxorubicin biosynthesis through P450-redox partner optimization and structural analysis of DoxA | Nature Communications

Read Also:

Sensation: Total synthesis of disorazol Z1 successful – MedLabPortal

Editor: X-Press Journalistenbüro GbR

Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.

Most read

Stay informed?

X
Ich bin Invi, wie kann ich dir helfen?